SEARCH

SEARCH BY CITATION

References

  • 1
    Martin, R., Mcfarland, H. F. and Mcfarlin, D. E., Immunological aspects of demyelinating diseases. Ann. Rev. Immunol. 1992. 10: 153187.
  • 2
    Grau-López, L., Raïch, D., Ramo-Tello, C., Naranjo-Gómez, M., Dàvalos, A., Pujol-Borrell, R., Borràs, F. E. et al., Myelin peptides in multiple sclerosis. Autoimm. Rev. 2009. 8: 650653.
  • 3
    Bahbouhi, B., Pettré, S., Berthelot, L., Garcia, A., Elong Ngono, A., Degauque, N., Michel, L. et al., T cell recognition of self-antigen presenting cells by protein transfer assay reveals a high frequency of anti-myelin T cells in multiple sclerosis. Brain 2010. 133: 16221636.
  • 4
    Bielekova, B., Sung, M. H., Kadom, N., Simon, R., Mcfarland, H. and Martin, R., Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J. Immunol. 2004. 172: 38933904.
  • 5
    Grau-López, L., Raïch, D., Ramo-Tello, C., Naranjo-Gómez, M., Dávalos, A., Pujol-Borrell, R., Borràs, F. E. et al., Specific T-cell proliferation to myelin peptides in relapsing-remitting multiple sclerosis. Eur. J. Neurol. 2011. 18: 11011104.
  • 6
    Katrych, O., Simone, T. M., Azad, S. and Mousa, S. A., Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes. CNS Neurol. Dis. Drug Targets 2009. 8: 512519.
  • 7
    Ulzheimer, J. C., Meuth, S. G., Bittner, S., Kleinschnitz, C., Kieseier, B. C. and Wiendl, H., Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies. BioDrugs 2010. 24: 249274.
  • 8
    Hong, J., Zang, Y. C., Nie, H. and Zhang, J. Z., CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA 2006. 103: 50245029.
  • 9
    Sinha, S., Subramanian, S., Proctor, T. M., Kaler, L. J., Grafe, M., Dahan, R., Huan, J., et al., Recombinant T-Cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS. J. Neurosci. 2007. 27: 1253112539.
  • 10
    Garren, H., Robinson, W. H., Krasulová, E., Havrdová, E., Nadj, C., Selmaj, K., Losy, J. et al., Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann. Neurol. 2008. 63: 611620.
  • 11
    Lutterotti, A., Sospedra, M. and Martin, R., Antigen-specific therapies in MS – current concepts and novel approaches. J. Neurol. Sci. 2008. 274: 1822.
  • 12
    Fischer, F. R., Santambrogio, L., Luo, Y., Berman, M. A., Hancock, W. W. and Dorf, M. E., Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression. J. Neuroimmunol. 2000. 110: 195208.
  • 13
    Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B., et al., Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000. 6: 11671175.
  • 14
    Turley and Miller. Prospects of antigen-specific tolerance based therapies for the treatment of multiple sclerosis. Results Probl. Cell Differ. 2010. 51: 217235.
  • 15
    Thomson, A. W. and Robbins, P. D., Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann. Rheum. Dis. 2008. 67(Suppl. 3): 9096.
  • 16
    Torres-Aguilar, H., Sánchez-Torres, C., Jara, L. J., Blank, M. and Shoenfeld, Y., IL-10/TGF-beta-treated dendritic cells, pulsed with insulin, specifically reduce the response to insulin of CD4+ effector/memory T cells from type 1 diabetic individuals. J. Clin. Immunol. 2010. 30: 659668.
  • 17
    Maldonado, R. A. and von Andrian, U. H., How tolerogenic dendritic cells induce regulatory T cells. Ad. Immunol. 2010. 108: 111165.
  • 18
    Hilkens, C. M., Isaacs, J. D. and Thomson, A. W., Development of dendritic cell-based immunotherapy for autoimmunity. Int. Rev. Immunol. 2010. 29: 156183.
  • 19
    Menges, M., Rossner, S., Voigtlander, C., Schindler, H., Kukutsch, N. A., Bogdan, C., Erb, K., et al., Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J. Exp. Med. 2002. 195: 1521.
  • 20
    Hill, M. and Cuturi, M. C., Negative vaccination by tolerogenic dendritic cells in organ transplantation. Curr. Opin. Organ. Transp. 2010, doi: 10.1097/MOT.0b013e32833f7114 [Epub ahead of print].
  • 21
    Harry, R. A., Anderson, A. E., Isaacs, J. D. and Hilkens, C. M., Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann. Rheum. Dis. 2010. 69: 20422050.
  • 22
    Gill, D. and Tan, P. H., Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target. Expert. Opin. Ther. Targets 2010. 14: 797824.
  • 23
    Adorini, L. and Penna, G., Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum. Immunol. 2009. 70: 345352.
  • 24
    Bartels, L. E., Hvas, C. L., Agnholt, J., Dahlerup, J. F. and Agger, R., Human dendritic cell antigen presentation and chemotaxis are inhibited by intrinsic 25-hydroxy vitamin D activation. Int. Immunopharmacol. 2010. 10: 922928.
  • 25
    Burton, J. M., Kimball, S., Vieth, R., Bar-Or, A., Dosch, H. M., Cheung, R., Gagne, D., et al., A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010. 74: 18521859.
  • 26
    Naranjo-Gómez, M., Raïch-Regué, D., Oñate, C., Grau-López, L., Ramo-Tello, C., Pujol-Borrell, R., Martínez-Cáceres, E. et al., Comparative study of clinical grade human tolerogenic dendritic cells. J. Transl. Med. 2011. 9: 89.
  • 27
    Yang, J. S., Xu, L. Y., Huang, Y. M., Van Der Meide, P. H., Link, H. and Xiao, B. G., Adherent dendritic cells expressing high levels of interleukin-10 and low levels of interleukin-12 induce antigen-specific tolerance to experimental autoimmune encephalomyelitis. Immunology 2000. 101: 397403.
  • 28
    Correale, J., Ysrraelit, M. C. and Gaitán, M. I., Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009. 132: 11461160.
  • 29
    Adorini, L. and Penna, G., Induction of tolerogenic dendritic cells by vitamin D receptor agonists. Handb. Exp. Pharmacol. 2009. 188: 251273.
  • 30
    Pedersen, A. W., Holmstrøm, K., Jensen, S. S., Fuchs, D., Rasmussen, S., Kvistborg, P., Claesson, M. H. et al., Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin. Exp. Immunol. 2009. 157: 4859.
  • 31
    Jin, O., Kavikondala, S., Sun, L., Fu, R., Mok, M. Y. Y., Chan, A., Yeung, J. et al., Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression. Lupus 2008. 17: 654662.
  • 32
    Huang, Y. M., Stoyanova, N., Jin, Y. P., Teleshova, N., Hussien, Y., Xiao, B. G., Fredrikson, S. et al., Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10. Clin. Exp. Immunol. 2001. 124: 306314.
  • 33
    Vaknin-Dembinsky, A., Murugaiyan, G., Hafler, D. A., Astier, A. L. and Weiner, H. L., Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. J. Neuroimmunol. 2008. 195: 140145.
  • 34
    Bartosik-Psujek, H., Tabarkiewicz, J., Pocinska, K., Stelmasiak, Z. and Rolinski, J., Immunomodulatory effects of vitamin D on monocyte-derived dendritic cells in multiple sclerosis. Mult. Scler. 2010. 16: 15131516.
  • 35
    Unger, W. W., Laban, S., Kleijwegt, F. S., van der Slik, A. R. and Roep, B. O., Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur. J. Immunol. 2009. 39: 31473159.
  • 36
    Hermans, G., Stinissen, P., Hauben, L., Van den Berg-Loonen, E., Raus, J. and Zhang, J., Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals. Ann. Neurol. 1997. 42: 1827.
  • 37
    Woltman, A. M., van der Kooij, S. W., de Fijter, J. W. and van Kooten, C., Maturation-resistant dendritic cells induce hyporesponsiveness in alloreactive CD45RA+ and CD45RO+ T-cell populations. Am. J. Transpl. 2006. 6: 25802591.
  • 38
    Sochorová, K., Budinský, V., Rovzková, D., Tobiasová, Z., Dusilová-Sulková, S., vSpivsek, R. and Bartruvnková, J., Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin. Immunol. 2009. 133: 6977.
  • 39
    Beverly, B., Kang, S. M., Lenardo, M. J. and Schwartz, R. H., Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int. Immunol. 1992. 4: 661671.
  • 40
    Penna, G. and Adorini, L., 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 2000. 164: 24052411.
  • 41
    Kebir, H., Ifergan, I., Alvarez, J. I. I., Bernard, M., Poirier, J., Arbour, N., Duquette, P. et al., Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann. Neurol. 2009. 66: 390402.
  • 42
    Van Gool, S., Maes, W., Ardon, H., Verschuere, T., Van Cauter, S. and De Vleeschouwer, S., Dendritic cell therapy of high-grade gliomas. Brain. Pathol. 2009. 19: 694712.
  • 43
    Smits, E. L., Anguille, S., Cools, N., Berneman, Z. N. and Van Tendeloo, V. F., Dendritic cell-based cancer gene therapy. Hum. Gene Therapy 2009. 20: 11061118.
  • 44
    Morelli, A. E. and Larregina, A. T., Apoptotic cell-based therapies against transplant rejection: role of recipient's dendritic cells. Apoptosis. 2010. 15: 10831097.
  • 45
    Marin-Gallen, S., Clemente-Casares, X., Planas, R., Pujol-Autonell, I., Carrascal, J., Carrillo, J., Ampudia, R., et al., Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes. Clin. Exp. Immunol. 2010. 160: 207214.
  • 46
    Stern, J. N., Keskin, D. B., Kato, Z., Waldner, H., Schallenberg, S., Anderson, A., von Boehmer, H., et al., Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells. Proc. Natl. Acad. Sci. USA 2010. 107: 1728017285.
  • 47
    Smith, C. and Miller, S., Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities. J. Autoimm. 2006. 27: 218231.
  • 48
    Soldevila, B., Alonso, N., Martínez-Arconada, M. J., Morillas, R. M., Planas, R., Sanmartí, A. M. and Martínez-Cáceres, E. M., A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment. J. Viral Hepat. 2011. 18: 384392.
  • 49
    Rothbard, J. B. and Busch, R., Binding of biotinylated peptides to MHC class II proteins on cell surfaces. Curr. Protoc. Immunol. 2001. Chapter 18: Unit 18.1.
  • 50
    Kessler, J. H., Benckhuijsen, W. E., Mutis, T., Melief, C. J. M., van der Burg, S. H. and Drijfhout, J. W., Competition-based cellular peptide binding assay for HLA class I. Curr. Protoc. Immunol. 2004. Chapter 18: Unit 18.12.